Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced that it has been awarded a Small Business Innovation Research (SBIR)...

- Members include world-leading experts in fields of immunotherapy drug discovery and development and commercial oncology therapeutics - - Dr. James Collins, a founder of the field of synthetic...

- 92,000 square-foot cGMP facility will be designed to support clinical and commercial-scale production of allogeneic CAR-NK cell pipeline - - Facility to initially focus on preclinical product...

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a leading engineered cell therapy company and a wholly-owned and independently operated...

- Senti Bio has designed a scalable process for efficient manufacturing of allogeneic CAR-NK cell pipeline - - Large scale expansion of PBMC-NK cells and UCB-NK cells may provide a scalable source...

- Deborah Knobelman, PhD, appointed Chief Financial Officer - - Curt Herberts, MBS, promoted to Chief Operating Officer and Philip Lee, PhD, promoted to Chief Technology Officer - SOUTH SAN...

- Using Logic Gating gene circuits, Senti Bio is engineering allogeneic CAR-NK cells to target and more precisely eliminate cancer cells while sparing healthy cells - - Using a Regulator Dial...

SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced the acceptance of five abstracts for presentation at upcoming virtual...

- Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies...

SOUTH SAN FRANCISCO, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced that results from its discovery-stage oncology program using allogeneic...